SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-067017
Filing Date
2021-12-22
Accepted
2021-12-22 16:15:12
Documents
6
Period of Report
2021-12-22

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea152900-6k_biondvax.htm 6-K 10334
2 PRESS RELEASE, DATED DECEMBER 22, 2021. ea152900ex99-1_biondvax.htm EX-99.1 21937
3 GRAPHIC image_001.gif GRAPHIC 121
4 GRAPHIC image_002.jpg GRAPHIC 5295
5 GRAPHIC image_003.jpg GRAPHIC 5295
6 GRAPHIC image_004.jpg GRAPHIC 5295
  Complete submission text file 0001213900-21-067017.txt   55949
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 211513422
SIC: 2836 Biological Products, (No Diagnostic Substances)